Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Court rules in favor of Qiagen in patent dispute

March 2025—Qiagen announced that the German Federal Patent Court has ruled in Qiagen’s favor in a patent dispute against SD Biosensor. The court’s decision upholds Qiagen’s intellectual property rights involving the German part of European patent EP 3 421 997, which protects key innovations in tuberculosis detection. Patents covering these innovations have been issued to Qiagen in several other countries, the company said in a press statement, and form part of a group of more than 120 patents currently issued for QuantiFeron.

Leica Biosystems launches HistoCore Chromax WS

March 2025—Leica Biosystems announced the next iteration in its staining and coverslipping portfolio, the HistoCore Chromax Workstation. The HistoCore Chromax WS includes a reagent management system and features graphical, touchscreen interfaces. It is for in vitro diagnostic use and available in select countries.

Illumina unveils spatial transcriptomics technology

March 2025—Illumina announced a new spatial technology program that the company says will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina Connected Multiomics, the spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity. The technology will allow researchers to examine the spatial proximity of millions of cells per experiment, enabled by a capture area nine times larger than existing technologies and with four times greater resolution. It is compatible with Illumina NextSeq and NovaSeq sequencers.

FDA clears BioFire FilmArray GI Panel Mid

March 2025—BioMérieux announced that its BioFire FilmArray Gastrointestinal (GI) Panel Mid has obtained FDA clearance. The molecular PCR test is capable of simultaneously detecting 11 pathogens directly from a stool sample from individuals presenting with signs or symptoms of gastrointestinal infection. It runs on the BioFire FilmArray 2.0 and Torch PCR platforms, requires about two minutes of hands-on time, and has an approximate run time of one hour. The panel will be commercially available in the United States at the

Roche unveils sequencing by expansion technology

March 2025—Roche unveiled a proprietary sequencing by expansion (SBX) technology that offers ultra-rapid, high-throughput sequencing that is flexible and scalable for a broad range of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing. The novel sequencing approach uses a sophisticated biochemical process to encode the sequence of a target nucleic acid molecule (DNA or RNA) into a measurable surrogate polymer called an Xpandomer.

Cision Vision introduces InVision, Vision Board

March 2025—Cision Vision has introduced its In­Vision imaging system and Vision Board. The technologies aim to enhance the efficiency and accuracy of lymph node dissections at the gross bench.

FDA clears Thermo Fisher SARS-CoV-2, flu A/B, RSV test

March 2025—Thermo Fisher Scientific has received FDA 510(k) clearance for the Applied Biosystems TaqPath COVID-19, Flu A, Flu B, RSV Select Panel. The real-time PCR-based multiplex test covers the detection and differentiation of SARS-CoV-2, influenza A and B, and respiratory syncytial virus and enables the detection of co-infection. The panel runs on the Applied Biosystems QuantStudio 5 Dx real-time PCR system.

Q-linea nabs second contract in U.S. for ASTar instrument

March 2025—Q-linea announced that it has signed a second commercial contract for its ASTar instrumentation in the United States. Installation and training in a multihospital system will take place by the end of the first quarter this year. The quantitative antimicrobial susceptibility test system uses high-speed, time-lapse microscopy imaging of organisms in positive blood culture samples to determine the minimum inhibitory concentration of specific antimicrobial-organism combinations.

Labcorp test for advanced solid tumors now for clinical use

March 2025—Labcorp announced that its Labcorp Plasma Complete is now available for clinical use. The assay is a ctDNA-based comprehensive genomic profiling solution for patients with advanced solid tumors. It detects genomic alterations in circulating tumor DNA across 521 genes and covers established and emerging biomarkers associated with FDA-approved therapies, guideline-driven treatments, and clinical trial eligibility.

MARKETPLACE

TRENDING